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ABSTRACT
Introduction: The differentiation of viral from
bacterial pneumonia is important in
determining whether antibiotics are
appropriate for treatment of these infections.
Advances in diagnostic technologies such as
respiratory panels (RP) utilizing polymerase
chain reactions to detect viruses and
determination of procalcitonin (PCT)
concentrations may aid in this differentiation.
However, some studies have shown limited
impact for this purpose and thus continuation
of antibiotics despite results suggesting viral
infection. Our objective was to characterize
clinician-prescribing behavior at our
institution once RP and/or PCT results were
known and suggestive of a viral respiratory
infection.
Methods: This retrospective analysis was based
upon records of hospitalized patients in whom
proven or possible respiratory infections as
indicated by RP testing, respiratory bacterial
culture or International Statistical Classification
of Diseases and Related Health Problems 9th
revision codes for acute infectious respiratory
illness was documented. Patients evaluated
were required to have a RP or PCT within the
first 72 h of presentation. Drug orders were
evaluated for discontinuation of antibiotic
therapy within 48 h of a procalcitonin
of\0.25 lg/mL, a positive viral RP result, or
both.
Results: Of 4869 patients with PCT and/or RP
results, 2031 were included. PCT and RP testing
were obtained in 503 and 1823 patients,
respectively, with 295 patients having both.
Results of these tests suggested 789 patients
were potential candidates for antibiotic
avoidance. These included 219 with a
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PCT\0.25 lg/mL, 601 with a positive viral RP
result, and 31 with both. Antibiotics were
administered to 307 patients (39%) within the
first 72 h. In these, antibiotics were
discontinued within 48 h of laboratory results
availability.
Conclusion: These results suggest that positive
viral RP and low PCT results are infrequently
associated with discontinuation of antibiotic
therapy in proven or possible respiratory
infections at our institution. Direct
interventions with clinicians are likely needed




Procalcitonin; Rapid diagnostics; Respiratory
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INTRODUCTION
Pneumonia remains among the top 10 most
common causes of mortality for all age groups
in the United States and the most common
infectious cause of mortality [1]. In the United
States in 2013, pneumonia was responsible for
1.1 million hospital admissions and 53,282
deaths [2]. Pneumonia is commonly caused by
viral or bacterial pathogens with the former
being responsible for 29–39% of cases [3, 4].
Clinical signs and symptoms associated with
the two etiologies are often indistinguishable
[5]. Physical examination, routine
microbiological testing of respiratory samples
and radiologic findings are not routinely
reliable in establishing an accurate diagnosis of
bacterial pneumonia [6–8].
Developments in diagnostics that may
assist in alleviating this situation have
arisen. Polymerase chain reaction (PCR)
technology has been adopted into clinical
use for the rapid identification of various
pathogens. Multiplex PCR technology has
recently been added to allow the
identification of a panel of potential
respiratory pathogens in contrast to older
PCR technologies that only identified a
single target [8]. Biomarkers have been
examined for their diagnostic utility as
another approach to differentiate bacterial
infections from other types of inflammatory
states. While biomarkers such as C-reactive
protein and erythrocyte sedimentation rate
are often elevated in both infectious and
noninfectious conditions, procalcitonin (PCT)
levels are routinely elevated in the presence
of bacterial infections while remaining low in
the setting of other types of inflammatory
processes [9–12]. The use of this test as a
decision tool has been established as a safe
method for ruling out bacterial infections and
thus reducing antibiotic use [13]. However,
while low serum levels of PCT are suggestive
of the absence of bacterial infection, it does
not exclude it, and therefore results should
always be used in conjunction with clinical
judgment with particular caution given in
interpreting these results in seriously ill
patients.
Despite the advances in and clinical
application of such diagnostic technologies, it
has been reported that many patients
nonetheless continue to receive antibiotic
therapy without regard to positive viral PCR
and/or low PCT results [14–16]. It was our
objective to determine the frequency of
changes in empiric antibiotic therapy for
known or proven cases of pneumonia once
results of respiratory panels (RP) and/or PCT
testing were known to the clinician and thus
determine the need for an active stewardship
intervention at our own institution.
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METHODS
Patient Population
This retrospective, single-center study was
performed at the Medical University of South
Carolina Hospital, a 709 bed tertiary and
quaternary academic medical center. The
average daily census rate is 627, with over
36,000 annual admissions. Average adult
inpatient length of stay, age and case-mix
index are 6.2 days, 52 years, and 1.9642,
respectively. A hospital’s case-mix index
represents the average diagnosis-related group
(DRG) relative weight for that hospital. It is
calculated by summing the DRG weights for all
Medicare discharges and dividing by the
number of discharges. It is used in
determining the allocation of resources to care
for and/or treat the patients in the group. This
study was reviewed and approved by the
institutional review board at our institution.
This article does not contain any new studies
with human or animal subjects performed by
any of the authors. Records accessed were from
patients 18 years of age or older with proven or
suspected respiratory infections as indicated by
PCR, respiratory bacterial culture, or the
International Statistical Classification of
Diseases and Related Health Problems 9th
revision (ICD-9) code for acute infectious
respiratory illness (ICD-9 codes 460–466 and
480–488) associated with a hospitalization
between January 01, 2012 and January 01,
2014. All patient records evaluated were
required to have a RP or PCT within the first
72 h of presentation. Patients with cystic
fibrosis based on ICD-9 or patients with
positive bacterial cultures were excluded.
Additionally, patients with COPD, chronic
bronchitis, or emphysema were excluded as a
lack of utility of PCT in distinguishing viral
from bacterial respiratory illness in COPD has
been described [17]. Basic study/design flow is
illustrated in Fig. 1.
Diagnostic Tests
Procalcitonin concentrations were determined
with the VIDAS BRAHMS PCT automated test
(bioMe´rieux, Marcy, France). PCT has a reported
sensitivity of 88% and specificity of 81% in
distinguishing a bacterial infection from other
inflammatory processes [18]. Routine laboratory
reporting denotes values of\0.25 lg/mL as
suggestive of a bacterial infection being
unlikely. PCT testing was generally available
within two hours once the specimen was
obtained. The presence of respiratory viruses
was determined with the FilmArray Respiratory
Panel (BioFire Diagnostics, Inc., Salt Lake City,
UT, USA), a multiplex PCR test. This test detects
17 viruses including Adenovirus, Coronavirus
229E, Coronavirus HKU1, Coronavirus NL63,
Coronavirus OC43, Human Metapneumovirus,
Influenza A, Influenza A subtype H1, Influenza
A subtype H3, Influenza A subtype 2009 H1,
Influenza B, Parainfluenza Virus 1,
Parainfluenza Virus 2, Parainfluenza Virus 3,
Fig. 1 Flow diagram for study design and data collec-
tion/analysis. COPD chronic obstructive pulmonary dis-
ease, ICD-9 International Classiﬁcation of Diseases 9th
Revision, PCT procalcitonin, RP respiratory panel
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Parainfluenza Virus 4, Rhinovirus/Enterovirus,
and Respiratory Syncytial Virus. Results were
available in one hour once specimen was
obtained with a sensitivity and specificity that
are 80–100% and 100%, respectively. No
institutional protocol or guidance on the use/
interpretation of PCT was in place at the time of
the study. Neither test had education provided
on their use during their implementation or
during our analysis period. No specific
antimicrobial stewardship activities or
initiatives were in place specific for these tests
during the study.
Data Collection
Patient data collected included age, sex,
co-morbid conditions, diagnoses, intensive
care unit admission, antibiotic use and
duration, and the results of bacterial cultures if
obtained, PCT, and RP. Drug orders were
evaluated for discontinuation of therapy
within 48 h of a procalcitonin of\0.25 lg/mL,
a positive viral result, or both. Data were
analyzed descriptively. Analysis was performed
in Excel 2013 (Microsoft, Redmond, WA, USA).
Figures were created using Excel 2013 and
Inkscape 0.91 (Free Software Foundation, Inc.,
Boston, MA, USA).
RESULTS
Of 4869 individual patient records with PCT
and/or RP results, 2031 met inclusion for the
study (Fig. 1). Results of PCT and RP testing
were available in 503 and 1823 patients,
respectively, with 295 patients having both. Of
tests performed in the first 72 h, the results
suggested that 789 (38.8%) patients may have
had opportunities for antibiotic avoidance. In
total, 219 patients with a PCT\0.25 lg/mL, 601
with a positive PCR, and 31 with both were
identified. Of patients with testing results in the
first 72 h, antibiotics were administered to 307
patients (38.9%) during the same period
(Table 1). The most frequently detected
respiratory viruses were influenza A/B (34% of
total) and rhinovirus/enterovirus (30%; Fig. 2).
Of the 307 patients prescribed antibiotics
within the first 72 h, antibiotics were
discontinued within 48 h of laboratory results
in 60 (19.5%) patients with either a PCT\0.25
lg/mL, a positive PCR, or both (Table 2). The
median duration of antibiotics was 3 days for all





PCT <0.25 lg/L and
positive viral RP
(n5 31)
Median age, years (IQR) 58 (44–69) 47 (33–60) 55 (41–67)
Male sex, n (%) 94 (42.0) 256 (42.6) 15 (48.4)
Charlson Score, median (IQR) 1 (1–2) 1 (0–1) 1 (1–2)
ICU admission during hospitalization,
n (%)
89 (40.6) 53 (8.8) 13 (41.9)
Median length of stay, days (IQR) 4 (2–6) 1 (0–3) 3 (2–6)
Antibiotic prescribed within ﬁrst 72 h 156 (71.2) 170 (28.2) 19 (61.3)
ICU intensive care unit, IQR interquartile range, PCT procalcitonin, RP respiratory panel
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of these groups and ranged from 1 to 19 days, 1
to 27 days, and 1 to 13 days for a PCT\0.25 lg/
mL, a positive RP, or both, respectively.
DISCUSSION
The problem of inappropriate use of antibiotics
leading to antibiotic-resistant organisms cannot
be overstated. This issue has escalated to being
nationally recognized and addressed in the
White House’s National Action Plan for
Combating Antibiotic-Resistant Bacteria,
which among other initiatives, calls for
increased antimicrobial stewardship activities
for the judicious use of antimicrobials and for
innovation in rapid diagnostics to facilitate that
effort [19]. In the outpatient setting including
the emergency department, the majority of
antibiotic prescribing has been for patients
presenting with respiratory conditions [20].
Many such infections are of viral origin
including nearly 30% of pneumonias [3, 4]. In
turn, much antibiotic prescribing for respiratory
infections in outpatients is unwarranted [21,
22]. Unnecessary antibiotic use in the
hospitalized patients with apparent respiratory
tract infections also occurs [23]. This overuse
can be explained to a large extent by the
inherent difficulty in clinically differentiating
bacterial from viral infection. At the same time,
it appears that the treatment of respiratory tract
infections represents a major area of
opportunity for more judicious and limited
use of antibiotics. The utilization of rapid
diagnostic tests may help with this differential.
The use of PCT and RP alone, or in
combination, has been successfully and safely
used to guide diagnosis and therapy [13, 24–27].
A number of studies have shown PCT to be an
effective test to utilize in altering antibiotic
prescribing patterns without adversely affecting
patient outcomes [13, 24, 25]. In these studies,
empiric antibiotics therapy was strongly
discouraged and/or recommended for
discontinuation in patients with low PCT
levels. Similar to the use of PCT to rule out
bacterial infections, positive results of RP have
been shown to be useful in efforts to reduce
antibiotic use as they provide direct proof of
viral respiratory infections. Afzal’s and
colleagues’ use of RP results led to a reduction
Fig. 2 Viruses identiﬁed by polymerase chain reaction
(percent of total)





PCT <0.25 lg/mL and
positive viral RP
(n5 31)
Antibiotics discontinued, n (%) 32 (20.5) 30 (17.6) 2 (10.5)
Median length of stay, days
(IQR)
4 (3–7) 4 (2–6) 5 (3–7)
IQR interquartile range, PCT procalcitonin, RP respiratory panel
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in antibiotic duration when that information
was made available to the primary care provider
[26]. Patients in whom the positive viral RP was
disclosed to the primary care provider (n = 11)
had a median duration of antibiotics of 7 days
as opposed to 12 days (P = 0.05) in patients
with proven bacterial infection (n = 28).
Furthermore, when a positive viral PCR was
not disclosed (n = 19), the median duration of
antibiotics was 12 days—similar to the bacterial
infection group. These findings of decreased
antibiotic exposure based on viral PCR were also
reported by Oosterheert and colleagues [27]. In
their study, positive PR results led to a
discontinuation of antibiotics in 11% of
patients.
One potential challenge of the reliance on
these rapid tests to rule out bacterial infection is
co-infection with viral and bacterial pathogens,
which has been reported in 14–40% of cases of
infectious pneumonia [14, 28, 29]. Co-infection
has recently been explored by Musher and
colleagues in a study analyzing the etiology of
community-acquired pneumonia (CAP) in a
cohort of hospitalized CAP patients in a US
Veterans Administration hospital [16]. Of 259,
4.6% were found to be co-infected with a virus
and a bacterium or fungus. However, in the 42
cases of viral infection, 12 (28.5%) had a
documented bacterial co-infection. In patients
with severe CAP requiring mechanical
ventilation, co-infection may occur more
often. In a study by Karhu and colleagues,
bacterial–viral co-infections were found in 39%
of patients [30]. Importantly, these investigators
reported that PCT concentrations actually
helped distinguish bacterial from non-bacterial
infections. Within their bacterial/viral
co-infection patients, median admission and
peak PCT concentrations were 20.1 and 24.3 lg/
L, respectively, while those values in the viral
infection group were 1.4 and 1.7 lg/L,
respectively. These data are consistent with
previous PCT data in suggesting that such
results are effective in discriminating between
viral and bacterial infections. However, it
should be noted that while many of the
aforementioned studies establish PCT as a safe
and effective way of ruling out bacterial
infections, others have cast doubt on
sensitivity [16, 31] with one group reporting a
sensitivity of approximately 40% [31]. Other
biomarkers may have a role in improving the
use of this test [32, 33].
We studied clinician-prescribing behavior at
our institution once RP and/or PCT laboratory
results were available to the prescribing
physician and were suggestive of a pure viral
respiratory infection. We observed antibiotic
discontinuation rates of only 17–20% in
patients with positive viral RP results or
PCT\0.25 lg/mL. In patients with both test
results available (n = 31), and highly suggestive
of a pure viral infection, antibiotic
discontinuation rates were even lower (10%).
One possible explanation for the low rates of
antibiotic discontinuation could relate to the
relatively low prescribing of antibiotics (38.9%)
to patients with proven or suspected respiratory
infections which had either a low PCT, a
positive viral RP result, or both. We believe
the relatively low incidence of prescribing in
this context suggests many prescribers avoided
antibiotic therapy based on other clinical
factors suggesting a non-bacterial illness
causing respiratory symptoms. An earlier study
by Falsey and colleagues of respiratory illness
reflected similar results to ours substantiating
the opportunity for more judicious
antimicrobial use based on the results of RP
and PCT [14]. In this single-center study,
patients were deemed to have a pure viral
infection if a viral test was positive, all
bacterial tests were negative, and serum PCT
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levels were\0.25 lg/mL on admission and day
two of hospitalization. Duration of inpatient
antibiotics was found to be significantly less in
the viral alone group as compared to the mixed
viral–bacterial group with means of 4.2 vs
6.2 days, respectively. These data suggest an
opportunity in the use of combining RP and
PCT results to narrow the etiologic diagnosis
and perhaps decrease unnecessary antibiotic
exposure. While mixed viral–bacterial
infection was noted in 40% of patients, the
utilized diagnostic battery appeared to
distinguish these from pure viral infections. It
is also notable, however, that while RP and PCT
results suggesting pure viral infections resulted
in shorter durations of antibiotic therapy, the
average duration of therapy extended more
than 2 days beyond the availability results of
RP and PCT testing. Recently, in a follow-up
study, antibiotic prescribing patterns associated
with low PCT and positive viral RP results in
patients with non-pneumonic lower respiratory
tract infections were characterized into two
groups of patients, one receiving standard of
care and the second receiving care specified by
use of PCT algorithms and viral testing [15]. The
investigators observed antibiotic
discontinuation rates of 57% when PCT
was\0.25 lg/mL and a positive viral RP was
reported. This was substantially different than
the 10% antibiotic discontinuation rate we
observed. Several differences in study methods
likely explain these disparate results.
Importantly, ‘‘nonpneumonic’’ was apparently
defined as those with clinically suggestive
symptoms of lower respiratory tract infection
with no clear evidence of or risk factors for
bacterial pneumonia. Further, as the previous
study [14] was conducted at the same
institution as this more recent study and the
methods and results of that study were shared
with medical staff prior to commencing the
latter study, a source of internal bias was likely
introduced that would have influenced
antibiotic usage/discontinuation rates. The
observation that usage/discontinuation rates
did not differ in the comparator groups may
substantiate that impression. At the same time,
these studies and the proactive intervention in
the second provides further evidence that some
proactive intervention, beyond the availability
of rapid diagnostic test results, can influence
prescribing behavior.
Our study is not without limitations. As it
was a retrospective, single-center study, the
prescribing behavior observed may very well
differ from that at other institutions. As we
excluded patients with chronic obstructive
pulmonary disease, chronic bronchitis,
emphysema, and cystic fibrosis, our results
cannot be generalized as relevant to
respiratory tract infections in these patient
populations. Our criteria for antibiotic
prescribing were based solely upon availability
of and values for three specific tests (PCT, RP,
bacterial culture). Some patients may have had
other indicators suggestive of bacterial
pulmonary infection such as severity of illness,
indicative signs or symptoms, imaging studies,
elevated white cells, or urinary bacterial
antigens and so on which would have likely
influenced decisions to use/continue antibiotic
therapy. We did not account for the influence
of such evidence on prescribing patterns in our
analysis and their potential impact is of obvious
importance. Additionally, we did not evaluate
the timing of antibiotic administration in
relation to time of availability of PCT or RP
test results. Early testing is optimal for ensuring
appropriate therapy decisions. However, studies
such as PRORATA [24] have used higher PCT
levels to determine appropriate antibiotic
discontinuation. Those data suggest that
regardless of the timing of administration of
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antibiotics, our more conservative PCT level
would have suggested an opportunity for
appropriate antibiotic discontinuation.
Moreover, the PCT level used here for
evaluation of antibiotic avoidance or
discontinuation is consistent with other
studies involving PCT guidance of therapy in
possible or proven respiratory tract infections
[15, 25, 34, 35]. Finally, to fully characterize the
true impact of PCT and PCR on antibiotic
prescribing, comparisons would need to
include all patients with PCR and PCT results,
not only those patients with results suggestive
of mono-microbial viral respiratory infections.
We believe that there are several potential
clinical implications of our findings. While
2031 patients had proven or presumed
respiratory tract infections, only 295 patients
had both RP and PCT testing. The challenge of
co-infections with viruses and bacteria denotes
the need for respiratory infection protocols
including both PCT and RP tests ordered in
the emergency department or upon admission
to ensure prompt results for assistance in the
clinical decision-making process and the
appropriate use of antibiotics. The combined
use of these tests upon admission could have
decreased antibiotic use by an average of 2 days
in most patients in our study with a positive
viral RP, a PCT\0.25 lg/L, or both. Given issues
with PCT sensitivity, it would appear prudent
that both tests be employed. With the low rate
of antibiotic discontinuation in the setting of
positive viral RP and\0.25 lg/mL PCT results,
there appears to be a need for education of
providers. This education should include
reviewing the etiologies of respiratory tract
infections, providing PCT testing and
interpretation information, and the need for
judicious use of antibiotics related to potential
complications and resistance development.
Finally, there is an opportunity for
antimicrobial stewardship programs (ASP).
ASPs can provide education for practitioners,
develop antibiotic guidelines, PCT/RP
algorithms, and proactively recommend
antibiotic discontinuation based upon proper
interpretation of PCT and RP test results.
Proactive intervention, such as that provided
by ASPs is important in ensuring meaningful
use of rapid diagnostics as opposed to a lack of
clinical benefit in the absence of such
ASP-facilitated interventions [36, 37].
CONCLUSION
Our findings suggest that PCT and RP results,
alone or in combination, when indicative of a
diagnosis of pure viral respiratory infections are
infrequently associated with discontinuation of
antibiotic therapy at our institution.
Demonstration of this prescribing behavior
suggests a possible opportunity for
antimicrobial stewardship in the development
of a clinical pathway or decision tool and the
provision of relevant education on the
importance of these tests as well as direct
intervention with clinicians with the goal of
lessening unnecessary antibiotic use. Additional
studies should evaluate variations in antibiotic
prescribing through the combination of RP and
PCT protocols in respiratory tract infections
along with stewardship activities of provider
education and response to RP and PCT results.
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